The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
The company will strengthen its position in the ‘green solvent’ market by increasing its capacity by 20% to 120,000 MTPA from 100,000 MTPA before the end of current fiscal
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
Ministry of Ayush signed a MoU with Ministry of Micro, Small & Medium Enterprises (MSME) for the promotion of Ayush enterprises.
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Govt committed to supporting pharma companies with industry-friendly policies
Subscribe To Our Newsletter & Stay Updated
